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Abstract: Hypoxia is a common feature of solid tumors and is associated with an increased risk of
metastasis and a poor prognosis. Recent imaging techniques revealed that bone marrow contains
a quite hypoxic microenvironment. Low oxygen levels activate hypoxia signaling pathways such
as hypoxia-inducible factors, which play critical roles in the key stages of metastatic dissemination
including angiogenesis, epithelial-mesenchymal transition, invasion, maintenance of cancer stem cells,
tumor cell dormancy, release of extracellular vesicles, and generation of pre-metastatic niches.
Hypoxia also affects bone cells, such as osteoblasts and osteoclasts, and immune cells, which also
act to support the development and progression of bone metastases. Paradoxically, hypoxia and
related signaling molecules are recognized as high-priority therapeutic targets and many candidate
drugs are currently under preclinical and clinical investigation. The present review focuses on our
current knowledge of the potential roles of hypoxia in cancer metastasis to bone by considering the
interaction between metastatic cancer cells and the bone microenvironment. Current therapeutic
approaches targeting hypoxia are also described.
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1. Introduction
Bone is one of the most common sites of cancer metastasis [1,2]. The majority of patients
(around 70%) with breast and prostate cancers and a substantial proportion of patients (30–40%)
with lung cancer eventually develop bone metastases [2]. Although bone metastases, per se, are rarely
responsible for cancer mortality, they are associated with significant morbidity by causing so-called
skeletal-related events (SREs), including hypercalcemia, pathological fractures, spinal compression,
and bone pain, indirectly leading to poor prognoses [2]. Therefore, the control of bone metastasis is a
critical component in cancer treatment. However, the mechanisms of bone metastasis have not been
fully elucidated.
In addition to genetic and epigenetic events, the microenvironment impacts cancer progression
and metastasis through a variety of mechanisms. Hypoxia, a condition of low oxygen tension, is a
hallmark of tumor microenvironments, which is caused by an imbalance between oxygen delivery and
consumption [3]. Intratumoral hypoxia is associated with a significantly increased risk of metastasis
and poor prognosis in cancer patients [4].
Several lines of evidence suggest that transcription factors hypoxia-inducible factors (HIFs),
mediate the primary response to hypoxia [4,5]. HIFs are composed of an oxygen-sensitive α subunit
(HIF-α) and a stable β subunit (HIF-1β). In mammals, three genes that encode HIF-α subunit proteins
have been identified. HIF-1α and HIF-2α are broadly expressed in many human cancers, whereas little
is known about HIF-3α [4,6]. Under normoxic conditions, HIF-α subunits are continuously degraded
by the ubiquitin-proteasome pathway. In contrast, under hypoxic conditions, HIF-α subunits are
stabilized, translocate to the nucleus, dimerize with HIF-1β, and initiate gene transcription by binding
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to hypoxia response elements (HREs). In addition to hypoxia, HIF-α subunits were shown to be
regulated by several non-hypoxic stimuli involving kinases and reactive oxygen species [7].
In this article, the most recent understanding of the role of a hypoxic microenvironment in the
development and progression of bone metastases is reviewed and discussed.
2. Basic Understanding of the Pathophysiology of Bone Metastasis
Once cancer cells metastasize to bone, they disrupt the physiological bone metabolism maintained
by osteoblasts and osteoclasts and establish a new cellular environment more favorable for the
progression of bone metastasis, the so-called “vicious cycle” [1]. In brief, osteoclast stimulating factors,
such as parathyroid hormone-related protein (PTHrP), secreted by metastatic cancer cells activate bone
destruction, leading to an increase in the release of bone-derived growth factors, including insulin-like
growth factors (IGFs) and transforming growth factor β (TGFβ), into the bone microenvironment.
These factors then act on cancer cells, thereby causing more aggressive cancer phenotypes and
further bone destruction. This theory suggests that osteoclasts play pivotal roles in the process
of bone metastasis.
3. Hypoxia and Cancer Metastasis
Accumulating evidence indicates that hypoxia enhances malignant phenotypes of cancer cells
through enhancing angiogenesis, epithelial–mesenchymal transition (EMT), invasion, cancer stem-like
phenotypes, tumor cell dormancy, release of extracellular vesicles (EVs), and generation of
pre-metastatic niches, most of which are HIFs-dependent and all of which are positively correlated
with cancer metastasis (Figure 1) [5,8].
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3.1. Angiogenesis
Because one of the reasons for hypoxia caused in solid tumors is compromised blood flow,
angiogenesis is an adaptive response, which stimulates O2 delivery and supports tumor growth.
HIFs function as master regulators of angiogenesis by upregulating the expression of genes involved
in angiogenic responses, such as vascular endothelial growth factor (VEGF), stromal-derived factor-1
(SDF-1), angiopoietin-2 (Ang-2), placental growth factor (PGF), platelet-derived growth factor (PDGF),
and stem cell factor (SCF) [5]. It has been well-described that angiogenesis is essential for cancer
metastasis [9]. There have also been several reports showing the relationship between angiogenesis
and bone metastasis. A preclinical study showed that the angiogenesis inhibitor TNP-470 suppressed
bone metastases of MDA-MB-231 human breast cancer cells [10]. The study, using clinical samples of
breast cancer, revealed that the microvessel density in the primary tumors had a strong correlation
with the occurrence of bone metastases [11].
3.2. EMT
EMT is the transition of epithelial cells to cells with mesenchymal phenotypes [12]. It has
been demonstrated that HIF-1 downregulates E-cadherin, a specific marker for epithelial cells,
by enhancing the expression of so-called EMT-activating transcription factors, including SNAI1,
SNAI2, TWIST, and ZEB1 [5,8]. Although the relationship with hypoxia and HIFs was not
determined, the overexpression of TWIST1 was shown to facilitate the development of bone metastases
of MDA-MB-231/B02 human breast cancer cells in mice through a mechanism dependent on
microRNA-10b (miR-10b) [13]. Liu et al. reported that the expression of ZEB1 in bone-metastatic
small cell lung cancer (SCLC) tissues and cell lines was higher than that in non-metastatic ones [14].
They also demonstrated that ZEB1 knockdown and ZEB1 overexpression inhibited and promoted
bone metastases of SBC-3 and SBC-5 human SCLC cells in mice, respectively [14].
3.3. Invasion
The local invasion of tumor cells from the primary tumors to the adjacent stroma is a first step
in the metastasis cascade. The degradation of extracellular matrix (ECM) is one of the mechanisms
that tumor cells utilize to accelerate the invasion. Several proteinases are involved in this process.
Among these enzymes, the expression of matrix metalloproteinases (MMPs), including MMP2,
MMP9 and MMP14, are regulated by HIFs [5]. HIFs also modulate ECM remodeling through
increased expression of prolyl-4-hydroxylases (P4HA1 and P4HA2), procollagen-lysine,2-oxyglutarate
5-dioxygenases (PLOD1 and PLOD2), and lysyl oxidases (LOX, LOXL2, and LOXL4), which are
required for cancer cell invasion [5].
3.4. Cancer Stem Cells (CSCs)
The cancer stem cell (CSC) hypothesis proposes that only a small fraction of tumor cells have
tumor-initiating potential and are able to self-renew and differentiate into the heterogeneous cell
populations that compose tumors [15]. These stem-like properties are required to initiate secondary
tumor formation in distant organs. Our preclinical studies demonstrated that cancer stem-like
phenotypes contribute to the development of bone metastases of human breast cancer MDA-MB-231
cells [16] and mouse breast cancer 4T1 and Jyg-MC(A) cells [17] in mice.
Hypoxia was shown to induce the cancer stem-like phenotypes in an HIF-dependent manner
firstly in glioma [18] and, subsequently, in several types of cancer, including breast cancer [19].
Hypoxia and HIFs promote the generation and maintenance of CSCs through the expression of genes,
including octamer-binding transcription factor 4 (OCT4), sex determining region Y-box 2 (SOX2),
and NANOG [20].
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3.5. Dormancy
Tumor dormancy is defined as a temporary mitotic and growth arrest, which might explain local
recurrences and metastases at different time points after treatment [21]. Metastases originate from
disseminated tumor cells (DTCs), which often undergo a period of dormancy [22]. Bone marrow is
one of the most frequent sites in which DTCs are detected [21]. In this case, bone can be a target organ
of metastasis, but it might also serve as a transit site from which cells can again disseminate to their
final metastatic organs.
It has been suggested that tumor cell dormancy is regulated by hypoxia. Fluegen et al. showed that
hypoxic microenvironments upregulate key dormancy genes, such as NR2F1, DEC2, and p27, in head
and neck and breast cancer cells in mice and humans, which was accompanied by the overexpression
of HIF-1 and glucose transporter 1 (GLUT1) [23]. Furthermore, post-hypoxic DTCs become quiescent
in metastatic sites and evade chemotherapy. Another group reported that several cycles of hypoxia and
re-oxygenation generate a hypoxia-resistant cell line, which can survive under hypoxic conditions by
entering into a dormant state that is reversible upon normoxia exposure [24]. In contrast, Johnson et al.
proposed the opposite effects of hypoxia on tumor cell dormancy in bone marrow [25]. They revealed
that leukemia inhibitory factor receptor (LIFR)-signal transducer and activator 3 (STAT3)-suppressor
of cytokine signaling 3 (SOCS3) signaling in DTCs confers a dormancy phenotype in response to LIF,
a member of the IL-6 family of cytokines and produced by osteoblast-lineage and bone marrow stromal
cells. The pathway is inhibited by hypoxia and HIF signaling, leading to the transition from a dormant
to an invasive phenotype. Further studies are required to clarify the complex relationships between
hypoxia and tumor cell dormancy.
3.6. Extracellular Vesicles (EVs)
EVs, including exosomes (30–100 nm diameter) and microvesicles (100–1000 nm diameter),
are cell-derived vesicles, which are now recognized as major players in cell–cell communication [26].
Cancer-associated EVs also promote angiogenesis, CSCs, EMT, and metastasis through their content,
such as various types of proteins, RNAs, and DNAs. EVs derived from prostate cancer (PC3),
myeloma (U266, MM1S, and OPM2), and lung cancer (CRL-2868) cells were shown to stimulate
osteoclast formation [27–29], whereas those from prostate cancer (TRAMP-C1) cells inhibited osteoclast
formation [30]. Exosomes derived from bone marrow stromal cells (BMSCs) in multiple myeloma
facilitated tumor growth, which was inhibited by exosomes from normal BMSCs [31]. Another report
revealed that exosomes from BMSCs promoted dormancy in metastatic breast cancer cells by
exosomal transfer of miRs [32]. Furthermore, Hashimoto et al. showed that exosomes from prostate
cancer cells containing hsa-miR-940 induced bone metastases with an osteoblastic phenotype [33].
These findings imply the presence of exosome-mediated complex cell–cell communication in the bone
metastatic microenvironment.
It has been reported that hypoxia increases the release of EVs from cancer cells [34]; however,
the contribution to metastatic bone diseases remains to be investigated.
3.7. Pre-Metastatic Niche
The pre-metastatic niche, a favorable microenvironment created in secondary organs for
subsequent metastases, is formed mainly by primary tumor-derived factors, tumor-mobilized bone
marrow-derived cells (BMDCs), and local stromal components [35]. Recent studies revealed that the
LOX family members, including LOX, LOXL2, and LOXL4, are key HIF-1-regulated genes involved in
BMDC recruitment to promote pre-metastatic niche formation [36]. LOX has also been shown to play
a role in the formation of pre-metastatic bone lesions, which will be described in detail in Section 6.
Int. J. Mol. Sci. 2018, 19, 3523 5 of 15
4. Hypoxia and Bone Cells
According to a study in which partial pressure of oxygen (pO2) in the calvariae of live mice was
measured using two-photon phosphorescence lifetime microscopy, the absolute pO2 in bone marrow
was <32 mmHg (4.2%) despite the high vascular density [37]. The heterogeneous pO2 in bone marrow
was lowest in deeper perisinusoidal regions (9.9 mmHg, 1.3%). These data indicate that bone is a quite
hypoxic microenvironment.
4.1. Effects of Hypoxia on Osteoclasts
Hypoxia was shown to increase osteoclast formation in vitro [38,39], which was supported
by findings that hypoxia stimulates the production of pro-osteoclastogenic cytokines, such as
receptor activator of nuclear factor-κB ligand (RANKL), VEGF, macrophage colony-stimulating
factor (M-CSF), IGF-2, and growth differentiation factor-15 (GDF-15), and inhibits the production
of osteoprotegerin (OPG), an inhibitor of osteoclast differentiation [40]. Furthermore, the report
by Miyauchi et al. suggested that hypoxia-induced osteoclast differentiation is mediated, at least
in part, by HIF-1α [41]. They further proposed that HIF-1α is required for osteoclast activation [41].
Several studies, including ours, demonstrated that acidosis caused by hypoxia also promoted osteoclast
formation and activity, which was mediated by the up-regulation of RANKL and nuclear factor of
activated T cells cytoplasmic 1 (NFATc1) [39,42]. Hypoxia most likely acts to enhance osteoclastic bone
destruction and bone metastasis (Figure 1).
4.2. Effects of Hypoxia on Osteoblasts
In vitro studies showed that hypoxia exhibited inhibitory effects on the differentiation and
bone-forming capacity of osteoblasts [39,43]. In contrast, mice with osteoblast-specific deletion of
von Hippel-Lindau (VHL) and osteoblast-specific overexpression of HIF-1α exhibited increased bone
volume and osteoblast numbers [44,45], suggesting that hypoxia and HIF-1α activation have positive
effects on bone formation in vivo. Further studies are required to explain the discrepancy between
in vitro and in vivo data.
A recent study by Devignes et al. demonstrated that activated HIF signaling in osteoblast-lineage
cells promotes bone metastases in mice [46]. Mechanistically, they found that activation of HIF
signaling in osteoprogenitor cells increased the production of C-X-C motif chemokine ligand
12 (CXCL12), which leads to an increase in proliferation and dissemination of breast cancer cells
through direct activation of C-X-C motif chemokine receptor 4 (CXCR4), a receptor for CXCL12. Of note,
these effects were also found in organs other than bone, such as lung, suggesting that HIF signaling in
osteoblast-lineage cells might cause tumorigenesis beyond the local bone microenvironment (Figure 1).
5. Hypoxia and Immune Cells in Bone
Bone is a unique organ, which belongs not only to the musculoskeletal system but also to
the immune system [47,48]. In bone, multiple types of immune cells and their progenitor cells
share the same microenvironment with bone cells. Recent emerging evidence suggests the mutual
relationship between bone and immune cells in their differentiation and function. Since 2000, the term
“osteoimmunology” has been used to describe this discipline [49]. Thus, as well as cancer cells and
bone cells, immune cells are one of the major players in metastatic bone lesions.
Malignant tumor cells have many mechanisms to make their microenvironment
immunosuppressive, including the ability to suppress immune responses through immune
check points, such as the cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death
protein 1 (PD1) pathways [50]. In addition, hypoxia has recently been implicated as an important
factor driving the immunosuppressive tumor microenvironment, which is created, at least in part,
by the infiltration of immunosuppressive cells, such as tumor-associated macrophages (TAMs),
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myeloid-derived suppressor cells (MDSCs), and regulatory T (Treg) cells [51]. However, little is known
about the involvement of these immune cells in bone metastasis (Figure 1).
5.1. TAMs
TAMs are macrophages infiltrating the tumor microenvironment. It has been demonstrated that
the density of TAMs correlates with poor prognosis in several types of cancer [52]. TAMs can be divided
into classically activated M1-like and alternatively activated M2-like subtypes [53]. M1-like TAMs
are known to exert anti-tumor activity by promoting proinflammatory effects and immune responses.
On the other hand, M2-like TAMs enhance tumor angiogenesis, matrix remodeling, tumor cell
migration and invasion, and immunosuppression, resulting in tumor progression. TAMs isolated
from established metastatic tumors are predominantly polarized to an M2-like phenotypes [53].
Several mediators, including interleukin-4 (IL-4) and IL-10, are involved in M2-like polarization.
Huber et al. reported that hypoxia induced the secretion of high mobility group box-1 (HMGB1)
from melanoma cells, which caused IL-10 production and M2-like TAM accumulation within the
tumor [54], suggesting that hypoxia contributes to the conversion of TAMs to an immunosuppressive
M2-like phenotype. Laoui et al. revealed that M2-like TAMs are preferentially attracted to hypoxic
regions [55]. Furthermore, tumor-derived lactic acid, whose levels are elevated by hypoxic metabolism,
promotes M2-like polarization in a HIF-1α-dependent manner [56]. These findings suggest that
hypoxia is associated with the accumulation of M2-like TAMs and enhances immunosuppressive
microenvironment. In addition, hypoxia is also shown to augment macrophage-mediated T-cell
suppression in a manner dependent on HIF-1α [57].
5.2. MDSCs
MDSCs are also tumor-infiltrating myeloid cells which impair immune responses through
various mechanisms [58]. HIF-1α has been reported to regulate the function and differentiation
of MDSCs within the hypoxic tumor microenvironment [59]. According to Corzo et al., tumor-derived
MDSCs possess higher immunosuppressive capacity than splenic MDSCs, which is mainly due to the
HIF-1α-dependent induction of arginase activity and nitric oxide (NO) production [59]. Furthermore,
Noman et al. showed that hypoxia upregulates the expression of programmed death-ligand 1 (PD-L1)
in MDSCs and increases MDSC-mediated T cell tolerance [60].
5.3. Tregs
Tregs are a highly immunosuppressive fraction of CD4+ cells [61]. In tumors, Tregs exhibit
activated phenotypes, including high expression of immune suppression-related molecules such as
CTLA-4. Several studies reported that hypoxia is associated with the selective accumulation of Tregs
in tumors, which not only suppresses antitumor responses but also promotes angiogenesis [62]. As a
mechanism, hypoxia was shown to potently increase the expression of forkhead box P3 (Foxp3),
a master regulator in the development and function of Tregs [63].
6. Hypoxia, HIFs, and Bone Metastasis
6.1. Hypoxia and Bone Metastasis
Intratumoral hypoxia is a common feature of cancers. According to Vaupel et al., overall median
pO2 in cancers, including uterine cervix, head and neck, and breast cancers, was 10 mm Hg, which was
markedly lower than that in normal tissues, which ranges from 24 to 57 mm Hg [64]. Although the
absolute values of pO2 in bone metastases in cancer patients are still unknown, our mouse study
revealed the presence of pimonidazole-positive hypoxic regions in the bone metastases of MDA-MB-231
cells in nude mice [39]. Because pimonidazole accumulates in cells that have pO2 less than 10 mmHg
(1.3%) [65], the result suggests that the hypoxic levels in bone metastases in this animal model are
equivalent to those in human cancers [64].
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As described in Section 3, hypoxia is closely associated with malignant behaviors
of cancer cells. Consistent with this notion, our previous study demonstrated that a
hypoxia-targeted agent, trans-activator of transcription (TAT)-oxygen-dependent degradation domain
(ODD)-procaspase-3 (TOP3), whose details will be described in Section 7, significantly reduced bone
metastases of MDA-MB-231 cells in mice [39]. Furthermore, as mentioned in Section 4, hypoxia and the
resulting metabolic acidosis stimulate the differentiation of osteoclasts, key players in the vicious cycle
of bone metastasis [1]. These data suggest the promoting roles of hypoxia in bone metastases; however,
our study did not fully address whether or how hypoxia in primary tumors controls spontaneous
metastasis to bone.
6.2. HIFs and Bone Metastasis
Gene expression analysis with cDNA microarrays showed that the expression of HIF-1α was
three-fold higher in primary tumors of breast cancer patients with bone micrometastases than in those
without the micrometastases, which was associated with the down-regulation of genes responsible
for HIF-1α degradation, such as VHL and cullin-2 [66]. The results suggest that HIF-1α may promote
tumor dissemination to bone.
In our preclinical model, an immunohistochemical study confirmed the nuclear HIF-1α expression
in tumor cells in the bone metastases of MDA-MB-231 cells in nude mice, which co-localized
or surrounded the pimonidazole-positive cells [39]. Furthermore, the stable expression of
constitutive-active HIF-1α increased and dominant-negative HIF-1α decreased the development
of bone metastases [39]. The results were confirmed by Lu et al.; although the effects were not specific
to metastases to bone [67]. They also identified two genes, dual specificity protein phosphatase
1 (DUSP1) and CXCR4, as hypoxia-activated bone metastasis-associated genes.
PTHrP is a potent stimulator of osteoclastic bone destruction and bone metastasis [68].
Manisterski et al. revealed that hypoxia enhanced the expression of PTHrP in cancer cells mediated
through HIF-2α but not HIF-1α [69]. It is well-known that PTHrP expression is also induced by TGFβ,
one of the growth factors abundantly stored in bone matrix and the key molecule in the vicious cycle of
bone metastasis [1]. Dunn et al. reported that hypoxia and TGFβ regulate a common set of tumor genes,
including PTHrP [70]. Furthermore, because inhibition of either pathway decreased bone metastases,
with no further effect of double blockade, they proposed that hypoxia and TGFβ signaling drives bone
metastases in parallel. Collectively, these results suggest the critical role of HIFs in bone metastases.
6.3. Emerging Roles of Lysyl Oxidase (LOX) in Bone Metastasis
LOX is a secreted copper-dependent amine oxidase, whose primary function is the covalent
crosslinking of collagens and elastins in the ECM [71]. However, recent studies demonstrated that
LOX also plays critical roles in hypoxia-induced cancer metastasis. Erler et al. firstly described that
LOX expression is regulated by HIF-1 and the inhibition of LOX eliminates metastasis in mice [72].
Mechanistically, LOX increases cell motility through up-regulating focal adhesion kinase activity and
cell-matrix adhesion. It was also revealed that LOX secreted by hypoxic cancer cells acts to form a
pre-metastatic niche by recruiting CD11b+ myeloid cells [73].
It has also been reported that LOX plays critical roles in cancer cell colonization in bone.
According to Cox et al., hypoxia is specifically associated with bone relapse in patients with estrogen
receptor (ER)-negative breast cancer [74]. Their study using spontaneously metastasizing ER-
breast cancer 4T1 cells, which express high levels of LOX, demonstrated that inhibition of LOX
by short hairpin RNA or anti-LOX antibody abrogates bone metastasis formation. Conversely,
experiments using SW480, a non-metastatic colon cancer cell line with low LOX expression,
showed that overexpression or systemic delivery of LOX leads to bone metastasis formation.
These findings are further supported by the report by Reynaud et al.; however, the effects were
independent of HIF-1 but dependent on LOX-driven IL-6 production [75]. They also revealed that
LOX stimulates osteoclastogenesis and inhibits osteoblastogenesis [74,75]. Thus, it is most likely
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that LOX-induced disrupted bone homeostasis leads to the formation of focal pre-metastatic lesions
in bone. Additionally, LOX is expressed in osteoblasts, which is induced by TGFβ released during
bone resorption [76]. The findings fit naturally into the vicious cycle theory. These results collectively
suggest the critical contribution of LOX to bone metastases. Thus, LOX could be a novel target for
therapeutic intervention [77].
It is of interest that an in vitro study by Cox et al. showed that LOX stimulated osteoclast
formation independently of RANKL, which was mediated through the direct action on NFATc1,
the master regulator of osteoclastogenesis [74]; however, later studies failed to reproduce these
findings [75,78]. There is a clear need for further study of the precise molecular mechanisms underlying
LOX-driven osteoclastogenesis.
7. Target Hypoxia
Considering the critical contributions as described above, hypoxia and HIFs are promising
therapeutic targets in treating bone metastases. One approach utilizes bioreductive or
hypoxia-activated prodrugs (HAPs) to eradicate hypoxic cells [79,80]. Another strategy is the inhibition
of HIFs and their downstream targets or upstream signaling molecules.
7.1. HAPs
HAPs are activated by enzymatic reduction at low oxygen tension. The majority of
HAP metabolites result in DNA damage by interfering with DNA replication. Several HAPs,
including AQ4N, PR-104, and TH-302 (evofosfamide), are currently undergoing clinical trials.
Some other compounds, such as TOP3, are also under development. However, to date, there are only a
few studies available that have investigated the effects on metastatic bone diseases.
7.1.1. AQ4N
AQ4N is enzymatically converted to a cytotoxic DNA-binding agent, AQ4, under hypoxic
conditions. AQ4 non-covalently binds to DNA to facilitate anti-tumor activity and selectively inhibits
the activity of the DNA separation enzyme topoisomerase II [81]. A phase I clinical trial in patients with
several types of solid tumors demonstrated that AQ4N was well-tolerated and activated selectively in
hypoxic regions in solid tumors [82,83].
7.1.2. PR-104
PR-104 is a phosphate ester that is hydrolyzed and reduced under hypoxic conditions to release
amine (PR-104M) and hydroxyl-amine (PR-104H) nitrogen mustards [80]. Subsequently, these reactive
nitrogen mustards crosslink DNA and cause cytotoxicity in cancer cells. According to a phase I/II
study in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), 32% of
AML patients and 20% of ALL patients showed response to treatment with PR-104 (ClinicalTrials.gov
NCT01037556) [84].
7.1.3. TH-302 (evofosfamide)
TH-302 is a 2-nitroimidazole prodrug that selectively releases bromo-isophosphoramide which
crosslinks DNA under hypoxic conditions [80]. A preclinical study showed that in vivo treatment of the
5T33MM mouse model of multiple myeloma with TH-302 induced apoptosis of tumor cells within the
bone microenvironment [85]. Furthermore, Liapis et al. demonstrated that TH-302 significantly delayed
the growth of human breast cancer MDA-MB-231-TXSA cells in mouse tibiae [86]. The combination
with paclitaxel exhibited greater inhibitory effects. However, phase III studies in advanced unresectable
or metastatic pancreatic adenocarcinoma (ClinicalTrials.gov NCT01746979) and in soft tissue sarcoma
(ClinicalTrials.gov NCT01440088) reported that TH-302 did not achieve primary overall survival
endpoints in combination with doxorubicin or gemcitabine [87].
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7.1.4. TOP3
TOP3 is a fusion protein that comprises of the protein transduction domain embedded in the
human immunodeficiency virus (HIV)-TAT protein, ODD, and procaspase-3 [88]. TOP3 is degraded
under normoxic conditions; however, under hypoxic conditions, the protein is stabilized and causes
caspase-3-induced cell death. Furthermore, because HIV-TAT fusion proteins freely diffuse through the
cell membrane, TOP3 can be delivered to tissues with compromised blood supply [89]. We reported
previously that TOP3 selectively induced apoptosis in hypoxic tumor cells in vitro and significantly
reduced bone metastases of MDA-MB-231 cells in mice [39].
7.2. Targeting HIFs
Although targeting HIFs themselves remains challenging, several clinical trials using
chemotherapeutic agents, such as CRLX101 (ClinicalTrials.gov NCT02187302) [90], letrozole [91],
bortezomib (ClinicalTrials.gov NCT00428545) [92], EZN-2208 (ClinicalTrials.gov NCT01251926),
temsirolimus (ClinicalTrials.gov NCT00761644) [92], and topotencan (ClinicalTrials.gov
NCT00436644) [93], which are expected to reduce the expression and/or transcriptional activity
of HIFs, have been conducted. Some of them showed favorable results.
As an approach to directly target HIFs, miRs have been investigated at preclinical levels [94].
Several miRs are induced in response to low oxygen, the majority of which are also overexpressed in a
variety of human tumors. Some of those, such as miR-26, -107, and -210, were shown to interfere with
pro-apoptotic signaling under a hypoxic environment, suggesting a possible involvement of these
miRs in tumor formation [95]. Zhou et al. reported that miR-33b targeted HIF-1α and inhibited the
proliferation and migration of osteosarcoma cells [96].
8. Conclusions
As well as tumor tissues, recent advances in imaging technology confirmed that bone is a generally
hypoxic microenvironment. The studies described above collectively suggest the critical roles of
hypoxia and related genes in promoting cancer metastasis; however, the specific contribution to bone
metastasis remains less clear. Continued studies to further understand specific mechanisms of the
roles of hypoxia in bone metastasis are clearly warranted and may likely lead to new and innovative
therapeutic strategies to block and cure bone metastasis.
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ALL acute lymphoblastic leukemia
AML acute myeloid leukemia
Ang angiopoietin
BMDCs bone marrow-derived cells
BMSCs bone marrow stromal cells
CSCs cancer stem cells
CTLA-4 cytotoxic T-lymphocyte antigen-4
CXCL12 C-X-C motif chemokine ligand 12
CXCR4 C-X-C motif chemokine receptor 4
DTCs disseminated tumor cells
DUSP1 dual specificity protein phosphatase 1
ECM extracellular matrix
EMT epithelial-mesenchymal transition
ER estrogen receptor
EVs extracellular vesicles
Foxp3 forkhead box P3
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GDF growth differentiation factor
GLUT1 glucose transporter 1
HAPs hypoxia-activated prodrugs
HIFs hypoxia-inducible factors
HIV human immunodeficiency virus
HMGB1 high mobility group box-1
HRE hypoxia response element
IGFs insulin-like growth factors
IL interleukin
LIFR leukemia inhibitory factor receptor
LOX lysyl oxidase
M-CSF macrophage colony-stimulating factor
MDSCs myeloid-derived suppressor cells
miR microRNA
MMPs matrix metalloproteinases
NFATc1 nuclear factor of activated T cells cytoplasmic 1
NO nitric oxide
OCT4 octamer-binding transcription factor 4
ODD oxygen-dependent degradation domain
OPG osteoprotegerin
P4HA prolyl-4-hydroxylase
PD1 programmed cell death protein 1
PDGF platelet-derived growth factor
PD-L1 programmed death-ligand 1
PGF placental growth factor
PLOD procollagen-lysine, 2-oxyglutarate 5-dioxygenase
pO2 partial pressure of oxygen
PTHrP parathyroid hormone-related protein
RANKL receptor activator of nuclear factor-κB ligand
SCF stem cell factor
SCLC small cell lung cancer
SDF-1 stromal-derived fator-1
SOCS3 suppressor of cytokine signaling 3
SOX2 sex determining region Y-box 2
SREs skeletal-related events
STAT3 signal transducer and activator 3
TAMs tumor-associated macrophages
TAT trans-activator of transcription
TGFβ transforming growth factor β
TOP3 TAT-ODD-procaspase-3
VEGF vascular endothelial growth factor
VHL von Hippel-Lindau
LD linear dichroism
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